Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures

Area of Science:

• Cardiology
• Cardiovascular Surgery
• Interventional Cardiology

Background:

• Management of antiplatelet therapy during cardiac device implantation is debated.
• Assessing bleeding risks associated with clopidogrel use in this context is crucial.

Purpose of the Study:

• To evaluate the risk of bleeding complications in patients receiving clopidogrel during cardiac device surgery.
• To identify factors associated with increased bleeding risk in this patient population.

Main Methods:

• Retrospective case-control study (2004-2010) of 101 patients on clopidogrel undergoing cardiac device surgery.
• 1:1 matching with controls based on age, sex, device, procedure, leads, and venous approach.
• Definition of significant bleeding complications included hematoma, hemothorax, pericardial effusion, or tamponade.

Main Results:

• Higher frequency of bleeding complications in the clopidogrel group (11.9% vs. 4.0%, P=0.037).
• Clopidogrel treatment (OR 3.7) and subclavian venous puncture (OR 3.44) were independent predictors of bleeding.
• Subclavian puncture was specifically linked to increased bleeding in clopidogrel users (P=0.008).

Conclusions:

• Clopidogrel use during heart rhythm device procedures is linked to increased significant bleeding.
• Subclavian venous puncture appears to be a significant risk factor for hemorrhagic complications in this setting.
• Careful management of antiplatelet therapy and venous access is recommended.